ClinicalTrials.gg
RecruitingNCT06145022Updated Nov 6, 2026

Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients

An interventional study of lifestyle modification and waitlist control group in Irritable Bowel Syndrome, sponsored by Universität Duisburg-Essen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Universität Duisburg-Essen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Irritable Bowel Syndrome with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Irritable Bowel Syndrome · Germany.

Planned enrollment
14th of 29
118 · median 100
Started
2024
with 1 other
No phase
13 of 37
2 open now
Registered
34th of 37
by date
Lead sponsor
8 of 37
Universität Duisburg-Essen

Among the 37 studies in Irritable Bowel Syndrome with a site in Germany, this one is the 14th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 34th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

4 of the 37 studies in Irritable Bowel Syndrome with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Irritable Bowel Syndrome with a site in Germany, or all of them as a file.
02

Study summary

In the planned efficacy study, a prospective randomized controlled trial will be conducted to investigate the extent to which a multimodal stress reduction and lifestyle modification program can be reflected in patients with irritable bowel syndrome (IBS) within the framework of a clinical study. For this purpose, 118 patients with IBS will be enrolled in a clinical study. The intervention group will participate in a partial outpatient multimodal stress reduction and lifestyle modification program over 10 weeks, while the waitlist control group will only receive an educational session and written information on treatment and self-help options. The primary research question encompasses the examination of the program's impact on the severity of symptoms associated with irritable bowel syndrome (measured with the IBS-Symptom Severity Scale [IBS-SSS]) and additionally its influence on quality of life, stress, and mental well-being. Another aspect of the study is the utilization of medical services (e.g., comparing the number of doctor visits; intake of prescribed and over-the-counter medications). Additionally, a comparison of days of work disability will be conducted.

Read the detailed description

The intervention is a 10-week multimodal stress reduction and lifestyle modification program consisting of 10 sessions, each lasting 6 hours. In groups of around 10 individuals, patients are comprehensively trained on the interplay between lifestyle and health, stress management, moderate physical activity (including yoga and Tai Chi), a Mediterranean diet, and self-help strategies. Successfully tested in two pilot studies, the program has evolved over 15 years and gained clinical experience in chronic inflammatory bowel diseases. It is now being applied to patients with irritable bowel syndrome (IBS).

Built on concepts like the Mind-Body Program and mindfulness-based stress reduction, the intervention incorporates elements from salutogenic and transtheoretical models and psychotherapeutic approaches.

Few integrative medicine approaches for IBS have undergone rigorous evaluation. IBS patients often experience reduced quality of life due to stress and psychosocial symptoms. The program, proven effective in inflammatory bowel diseases, covers stress reduction, dietary improvement, physical activity promotion, self-care applications, coping strategy training, and naturopathic treatments. Medically supervised, the group setting aims to enhance the intervention's impact through mutual support. Practical skills are demonstrated, and the goal is to empower patients for active, responsible, long-term management.

Participants in the waitlist control group receive a 1,5-hour educational session on lifestyle factors' influence and self-help materials. After week 36 measurements, they are offered participation in the multimodal program.

Questionnaires, a diary, and interviews will measure the outcomes of the study. Sociodemographics will be collected.

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • lifestyle modification
  • Mind-Body medicine
  • integrative medicine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of irritable bowel syndrome (IBS with diarrhea, IBS with constipation, mixed-type IBS, or unspecified IBS); IBS-SSS Score > 75

Exclusion criteria

Exclusion Criteria:

  • Severe mental illness (e.g., depression, substance use disorder, schizophrenia)
  • Severe comorbid somatic illness (e.g., oncological disease)
  • Pregnancy
  • Participation in other stress reduction programs or clinical studies on psychological interventions
  • Known intolerances (fructose, lactose), celiac disease, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    intervention group

    Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.

    Behavioral: lifestyle modification

  • Active comparator
    waitlist control group

    A unique education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.

    Behavioral: waitlist control group

Interventions

  • Behaviorallifestyle modification

    The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.

  • Behavioralwaitlist control group

    Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.

06

What researchers measure

Primary outcomes

  1. Severity of IBS symptoms by IBS-SSS

    Irritable bowel syndrome severity scoring system (IBS-SSS); 5-item questionnaire; scale from 0% (= not at all) to 100% (= very severe); cut-off of IBS-SSS scores to evaluate the severity of IBS: \< 175 for mild IBS, 175-300 for moderate IBS, and \> 300 for severe IBS

    Time frame: week 0

  2. Severity of IBS symptoms by IBS-SSS

    Irritable bowel syndrome severity scoring system (IBS-SSS); 5-item questionnaire; scale from 0% (= not at all) to 100% (= very severe); cut-off of IBS-SSS scores to evaluate the severity of IBS: \< 175 for mild IBS, 175-300 for moderate IBS, and \> 300 for severe IBS

    Time frame: week 12

  3. Severity of IBS symptoms by IBS-SSS

    Irritable bowel syndrome severity scoring system (IBS-SSS); 5-item questionnaire; scale from 0% (= not at all) to 100% (= very severe); cut-off of IBS-SSS scores to evaluate the severity of IBS: \< 175 for mild IBS, 175-300 for moderate IBS, and \> 300 for severe IBS

    Time frame: week 36

  4. overall change in health status

    Rating scale from 1 (= much worse) to 5 (= much better)

    Time frame: week 12

  5. overall change in health status

    Rating scale from 1 (= much worse) to 5 (= much better)

    Time frame: week 36

Secondary outcomes

  1. Disease related Quality of Life by IBS-QOL

    The IBS-QOL is a self-report quality-of-life measure specific to Irritable Bowel Syndrome (IBS) that can be used to assess the impact of IBS and its treatment. 34 items with a 5-point response scale from 1 (=not at all) to 5 (= Extremely/a great deal); 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.

    Time frame: week 0

  2. Disease related Quality of Life by IBS-QOL

    The IBS-QOL is a self-report quality-of-life measure specific to Irritable Bowel Syndrome (IBS) that can be used to assess the impact of IBS and its treatment. 34 items with a 5-point response scale from 1 (=not at all) to 5 (= Extremely/a great deal); 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.

    Time frame: week 12

  3. Disease related Quality of Life by IBS-QOL

    The IBS-QOL is a self-report quality-of-life measure specific to Irritable Bowel Syndrome (IBS) that can be used to assess the impact of IBS and its treatment. 34 items with a 5-point response scale from 1 (=not at all) to 5 (= Extremely/a great deal); 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.

    Time frame: week 36

  4. General Quality of Life by EQ-5D-SL

    The EQ-5D assesses health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and is considered a 'generic' questionnaire because these dimensions are not specific to any one patient group or health condition. 5-point response-scale from 1 (=not /no problems) to 5 (=unable to \[mobility, self-care, usual activities\]/extreme \[pain/depression\]/extremely \[anxiety/depression\]); result: 5-digit health status profile that represents that person's level of reported problems on the five EQ-5D health dimensions

    Time frame: week 0

  5. General Quality of Life by EQ-5D-SL

    The EQ-5D assesses health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and is considered a 'generic' questionnaire because these dimensions are not specific to any one patient group or health condition. 5-point response-scale from 1 (=not /no problems) to 5 (=unable to \[mobility, self-care, usual activities\]/extreme \[pain/depression\]/extremely \[anxiety/depression\]); result: 5-digit health status profile that represents that person's level of reported problems on the five EQ-5D health dimensions

    Time frame: week 12

  6. General Quality of Life by EQ-5D-SL

    The EQ-5D assesses health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and is considered a 'generic' questionnaire because these dimensions are not specific to any one patient group or health condition. 5-point response-scale from 1 (=not /no problems) to 5 (=unable to \[mobility, self-care, usual activities\]/extreme \[pain/depression\]/extremely \[anxiety/depression\]); result: 5-digit health status profile that represents that person's level of reported problems on the five EQ-5D health dimensions

    Time frame: week 36

  7. Stress: Perceived Stress (PSS-10)

    Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (= never) to 5 (=very often), high stress is assumed from a total score of 20 points

    Time frame: week 0

  8. Stress: Perceived Stress (PSS-10)

    Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (= never) to 5 (=very often), high stress is assumed from a total score of 20 points

    Time frame: week 12

  9. Stress: Perceived Stress (PSS-10)

    Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (= never) to 5 (=very often), high stress is assumed from a total score of 20 points

    Time frame: week 36

  10. Stress: Coping Strategies (CISS)

    Short version of the Coping Inventory for Stressful Situations (24 items); Rating on a five-step scale from 1 (= not at all) to 5 (= very much); sum score for each coping strategy; higher scores indicate a greater use of that particular coping strategy

    Time frame: week 0

  11. Stress: Coping Strategies (CISS)

    Short version of the Coping Inventory for Stressful Situations (24 items); Rating on a five-step scale from 1 (= not at all) to 5 (= very much); sum score for each coping strategy; higher scores indicate a greater use of that particular coping strategy

    Time frame: week 12

  12. Stress: Coping Strategies (CISS)

    Short version of the Coping Inventory for Stressful Situations (24 items); Rating on a five-step scale from 1 (= not at all) to 5 (= very much); sum score for each coping strategy; higher scores indicate a greater use of that particular coping strategy

    Time frame: week 36

  13. Core Self-Evaluation by CSES

    Core Self-Evaluation (CSES), 12 items on five-point Likert scale, 1 indicates disagreement and 5 indicates full agreement. High scores on the CSES represents a positive, confident, and self-efficacious person

    Time frame: week 0

  14. Core Self-Evaluation by CSES

    Core Self-Evaluation (CSES), 12 items on five-point Likert scale, 1 indicates disagreement and 5 indicates full agreement. High scores on the CSES represents a positive, confident, and self-efficacious person

    Time frame: week 12

  15. Core Self-Evaluation by CSES

    Core Self-Evaluation (CSES), 12 items on five-point Likert scale, 1 indicates disagreement and 5 indicates full agreement. High scores on the CSES represents a positive, confident, and self-efficacious person

    Time frame: week 36

  16. Utilization of medical services

    Number of visits

    Time frame: week 0

  17. Utilization of medical services

    Number of visits

    Time frame: week 12

  18. Utilization of medical services

    Number of visits

    Time frame: week 36

  19. Days of work disability

    Number of days

    Time frame: week 0

  20. Days of work disability

    Number of days

    Time frame: week 12

  21. Days of work disability

    Number of days

    Time frame: week 36

  22. Anxiety and depression by HADS

    Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety.

    Time frame: week 0

  23. Anxiety and depression by HADS

    Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety.

    Time frame: week 12

  24. Anxiety and depression by HADS

    Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety.

    Time frame: week 36

  25. Qualitative Interviews

    Qualitative interviews for gaining further insights into patients experiences

    Time frame: week 12

  26. Adverse events

    all adverse events

    Time frame: week 12

  27. Adverse events

    all adverse events

    Time frame: week 36

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 33 months is above that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Nov 2023 → Mar 2024, primary completion Dec 2024 → Dec 2026 and completion Jul 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 22, 2023
StartActual
Mar 6, 2024was Nov 2023
Primary completionEst.
Dec 31, 2026was Dec 2024
CompletionEst.
Aug 31, 2027was Jul 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 10, 2023→Mar 6, 2024
Nov 6, 2026
Primary completion
Dec 31, 2024→Dec 31, 2026
Nov 6, 2026
Study completion
Jul 31, 2025→Aug 31, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Nov 10, 2023→Mar 6, 2024
    Primary completion Dec 31, 2024→Dec 31, 2026
    Study completion Jul 31, 2025→Aug 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06145022
Lead sponsor
Universität Duisburg-Essen
Collaborators
Bavarian State Ministry of Health and Care
Responsible party
Jost Langhorst (Prof. Dr. med., Universität Duisburg-Essen) — Principal investigator
First posted
Nov 22, 2023
Start date
Mar 6, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Sandra Utz, PhD
Contact
sandra.utz@sozialstiftung-bamberg.de
+49 951 503 ext. 16926
Christine Uecker
Contact
christine.uecker@sozialstiftung-bamberg.de
+49 951 503 ext. 16932
Jost Langhorst, Prof. Dr.
principal investigator · University of Duisburg-Essen/Sozialstiftung Bamberg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion